▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1581 by analyst upside · 2026-11-13
RVMD
Revolution Medicines, Inc.
Healthcare · Market Cap $38B · P/E 0x
ANALYST PRICE TARGET
+55.9%
implied upside to consensus target
Current Price $176.35
Consensus Target $274.84
Bull Target $350.0
Bear Target $179.0
Analysts Covering 24
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
18
Hold
1
Sell
0
52-Week Low $63.5
52-Week High $224.31
YTD Return +123.2%
FUNDAMENTALS
Market Cap $38B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-9.13
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $198M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $63.5
52-Week High $224.31
Current Price $176.35
Bear Target $179.0
Bull Target $350.0
● Now $176.35 ● Target $274.84
TRADING DATA
Avg Volume 2.1M
YTD Return +123.2%
Analyst Count 24
Consensus Buy
Upside to Target +55.9%
Last Updated 2026-11-13

ANALYST SUMMARY

Revolution Medicines, Inc. (RVMD) is currently trading at $176.35 with a Wall Street consensus price target of $274.84, implying potential upside of 55.9% over the next 12 months. 24 analysts currently cover RVMD, with a consensus rating of Buy - 96% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $350.0, while the most cautious has a target of $179.0.

RVMD operates in the Healthcare sector with a market capitalisation of $38B. The stock is up 123.2% year-to-date and is currently trading near the upper end of its 52-week range of $63.5 – $224.31.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RVMD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. - Reiterated
Buy → Buy 2026-11-06 31% win rate (48 calls)
TD Cowen - Reiterated
Buy → Buy 2026-11-05 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-11-05 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-11-05 14% win rate (7 calls)
Truist Securities reit
Buy → Buy 2026-11-05 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-11-05 62% win rate (8 calls)
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-11-05 Building track record
TD Cowen reit
Buy → Buy 2026-10-21 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
58
out of 100
Coverage depth
25/30
Consensus clarity
11/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →